Scottish+ Radiotherapy Physics Meeting 2020 Feb 21, 2020 09:30 AM - 05:00 PM — Scottish Health Service Centre , Western General Hospital, Edinburgh
2nd Scottish Ultrasound Annual Scientific Meeting Feb 28, 2020 10:00 AM - 05:00 PM — Collins Building, University of Strathclyde
Technology Innovations for Healthcare Mar 12, 2020 09:00 AM - 05:00 PM — Royal College of Physicians, Edinburgh
8th Annual Scottish Radiotherapy Research Forum Mar 12, 2020 10:00 AM - 04:30 PM — Stirling Court Hotel, University of Stirling
Medical Imaging Convention 2020 Mar 17, 2020 10:00 PM - 04:00 PM — National Exhibition Centre, Birmingham, England


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke - Where do we go from here? A cumulative meta-analysis

Author(s): J. M. Wardlaw, P. A. G. Sandercock, E. Berge

Background and Purpose - Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely used in clinical practice as it could be. Have new data since 1995 strengthened the evidence sufficiently to justify more widespread use of rtPA? Methods - We performed a sequential year-to-year cumulative meta-analysis of randomized controlled trials of rtPA in acute ischemic stroke. Results - Although the amount of data has doubled since 1995, effect estimates for key outcomes remain imprecise, and significant between-trial heterogeneity persists. In the most recent analysis, rtPA up to 6 hours after stroke yielded 55 fewer dead or dependent people per 1000 treated (95% CI, 18 to 92) despite some risk ( nonsignificant excess of 19 deaths per 1000 patients treated; 95% CI, 6 fewer to 48 more). Severity of stroke, patient age, and aspirin use were possible sources of heterogeneity. Conclusions - Despite doubling of the data since 1995, the magnitude of risks and benefits with rtPA remains imprecise. This gap in knowledge may be hindering clinical use of rtPA and can be filled only by new trials designed to address these specific issues.

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 0039-2499
Publication Year: 2003
Periodical: Stroke
Periodical Number: 6
Volume: 34
Pages: 1437-1442
Author Address: